RheumNow Podcast – Loretta Lynn Arthritis (3.29.19) Save

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

1. 340 CCP+ persons without followed for 1047 PYrs = 21.5% developed RA. Risk of RA progression increased w/ CCP level. 46.0% of high level CCP patients progressedto RA by 5 years. High vs low CCP were 5 times more likely to get RA (HR 4.83, 95%CI 2.51-9.31). https://buff.ly/2FI5Dix 
2. Claims data analysis of 11,248 matched patients starting abatacept or TNFi showed the risk of hospitalized infection was 37 ABA vs 47 TNFi (HR 0.78; 95% CI 0.64-0.95). Thus ABA was associated with a 22% less risk any hospitalized infection. https://t.co/Ij6b0IYcAZ 
3. 2019 Doximity report shows Rheumatologists are the 14th lowest paid of all medical specialties; but is amongst the lowest with a gender gap difference. check it out here https://t.co/j3YOybQ78n 
4. Murine BM–derived macrophages or human monocytes treated w/ tofacitinib or selective JAK1, JAK3 inhibitors. Both TOFA & JAK1i but not JAK3i effectively inhibited STAT1 phosphorylation & IFN gamma production, suggesting affects on macrophage function. https://t.co/qILxzCDrCH   
5. Boehringer Ingelheim announce s FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD https://t.co/BQz94Kg4Px     
6. After either RTX or CTX induction, 102 pts w/ ANCA-associated vasculitis were give maintenance w/ azathioprine plus belimumab or placebo. Belimumab did not reduce the flare rate (HR=1.07;) or relapse (HR=0.88) (NS) in these patients https://t.co/5EgdzRRXq8   
7. Coal miners at higher risk for any arthritis (HR 2.3) and rheumatoid arthritis (HR 3.6) https://t.co/OKx9LiADWw 
8. Serum soluble programmed cell death protein 1 (sPD-1) shown to correlate w/ BVAS activity in 59 pts w/ ANCA-associated vasculitis (AAV). sPD-1 was correlated with hemoglobin and serum albumin, but not ESR or CRP. https://t.co/GOShh8Kwb2 
9. Prevalence of gout continues to rise. NHANES data say prevalence of gout is 9.2 million inUS adults (2015-2016) (5.9 mill men; 3.3 mil women); hyperuricemia prevalences is 20.0%. ULT use in gout was 33% between 2007-2014. https://t.co/nDEJM7gTGA   
10. FDA Approves Cimzia for Non-Radiographic Axial Spondyloarthritis